Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD

Overview

This proposal will evaluate a potential mechanism of increased risk of lung function impairment, cathelicidin levels, as well as determine if vitamin D replacement can alter this pathway. This study will improve the understanding of factors which can lead to chronic lung disease. If effective, this application would also provide the justification to study vitamin D as a therapy to improve lung health.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 15, 2020

Detailed Description

Understanding mechanisms leading to decrements in lung function, the physiologic hallmark of obstructive lung diseases including chronic obstructive pulmonary disease (COPD), are necessary to inform interventions to improve lung health. The antimicrobial peptide cathelicidin, and its primary regulator vitamin D, has been implicated in development and progression of chronic lung disease. In this study, the investigators will evaluate the effect of oral vitamin D supplementation on lung cathelicidin levels in humans. Cathelicidin has bactericidal and inflammatory activities in the lung and is regulated by vitamin D levels. The investigators hypothesize that oral vitamin D supplementation will raise cathelicidin levels in the pulmonary compartment, thereby restoring lung cathelicidin deficiency. To test this hypothesis, the investigators will recruit from two ongoing cohort studies: 1) At Johns Hopkins, the Subpopulations and Intermediate Outcome Measures in COPD Study study and 2)at University of North Carolina at Chapel Hill pulmonary and general medicine clinic. The investigators will measure blood and lung lavage cathelicidin levels in 40 vitamin D insufficient individuals (20 from each cohort) before and after eight weeks of oral vitamin D supplementation to determine the effect of vitamin D supplementation on cathelicidin levels.

Interventions

  • Drug: Vitamin D3
    • Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.

Arms, Groups and Cohorts

  • Experimental: Vitamin D3
    • Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline in Lung Cathelicidin Level at 8 Weeks
    • Time Frame: Baseline and 8 weeks
    • Change from baseline to 8 weeks in bronchoscopic lavage lung cathelicidin levels after vitamin D supplementation (comparison between pre- and post-supplementation cathelicidin levels using paired t-tests for repeated measures)

Secondary Measures

  • Change From Baseline in Blood Cathelicidin at 8 Weeks
    • Time Frame: Baseline and 8 weeks
    • Change from baseline to 8 weeks in blood cathelicidin levels after vitamin D supplementation (comparison between pre- and post-supplementation cathelicidin levels using paired t-tests for repeated measures)
  • Change From Baseline in Blood Vitamin D Binding Protein at 8 Weeks
    • Time Frame: Baseline and 8 weeks
    • Change from baseline to 8 weeks in blood vitamin D binding protein after vitamin D supplementation (comparison between pre- and post-supplementation cathelicidin levels using paired t-tests for repeated measures)

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women age 18-65 who are current or former smokers – Serum calcium<10.5mg/dL – 25-Hydroxy Vitamin D (OHD)<20 ng/mL – Creatinine Clearance ≥60 mL/min as estimated by the Cockcroft-Gault equation – Women of reproductive potential with negative serum or urine pregnancy test and subjects must refrain from participating in a conception process and subject/partner must use at least 2 reliable forms of contraceptives for the duration of the study – For participants with COPD, Forced Expiratory Volume in 1 second (FEV1) greater than 50% predicted. – For smokers, current cigarette use (defined as regularly smoking 5 cigarettes per day) Exclusion Criteria:

  • Current use of vitamin D supplements – Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulations – Pregnancy or currently breast-feeding – History of nephrolithiasis – HIV positive serostatus – Continuous oxygen use >2 liters/min via nasal cannula – Any condition that, in the opinion of the site investigator, would compromise the subject's ability to participate in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of North Carolina, Chapel Hill
  • Collaborator
    • Johns Hopkins University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michael B Drummond, MD, Principal Investigator, University of North Carolina, Chapel Hill

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.